PMA device
Ams Urolume Endoprosthesis
Boston Scientific Corp · Stent, Urethral, Bulbous, Permanent Or Semi-Permanent (MES, Class III) · First FDA decision Nov 23, 2011, newest Nov 23, 2011Enlarged prostate (BPH)
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Ams Urolume Endoprosthesis"
MAUDE reports
2
Brand "Ams Urolume Endoprosthesis", since 2015
PubMed studies
0
Mentioning "Ams Urolume Endoprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Ams Urolume Endoprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- AMS UROLUME ENDOPROSTHESISPMA supplement
P920023-S023 · Decided Nov 23, 2011 · 1,337 days after receipt · Normal 180 Day Track No User Fee
Device type: STENT, URETHRAL, BULBOUS, PERMANENT OR SEMI-PERMANENT (MES) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Ams Urolume Endoprosthesis", any status and sponsor, newest update first.
No registered device study names "Ams Urolume Endoprosthesis".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Ams Urolume Endoprosthesis", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code MES
3 reports: 1 malfunction, 2 injury, 0 death
Newest reports for this brand
BOSTON SCIENTIFIC - MINNETONKA
2183959-2017-00094 · Received Oct 10, 2017
Device type: Stent, Urethral, Bulbous, Permanent Or Semi-Permanent (MES)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Incontinence; Burning Sensation; Stenosis; Dysuria
2183959-2015-00403 · Received Sep 25, 2015 · Event dated Jul 1, 2015
Device type: Stent, Urethral, Bulbous, Permanent Or Semi-Permanent (MES)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Dysuria; No Code Available
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Ams Urolume Endoprosthesis"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MES.
- Urolume(R) EndoprosthesisBoston Scientific Corp · PMA 2001
- Urolume Endourethral Prosthesis for Prostatic Obstruction Secondary to Benign Prostatic HypertrophyBoston Scientific Corp · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.